Boston Scientific Corporation BSX
Verdict: Sell. Fair value $77.44 against a price of $95.48 on 5 Jan 2026, 19% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Consistent earnings beats of exactly +0.0% to +0.1% over 4 quarters suggests aggressive guidance.... Financial data is 97 days old, indicating analysis relies on trailing data that may not reflect the....
Main risks
- Valuation Premium: Trading at ~76x trailing GAAP Earnings and ~39x TTM FCF, pricing in perfection.
- Low GAAP ROE: 8.5% ROE is significantly below high-quality MedTech peers, though FCF conversion is strong.
- Data Discrepancy: TTM Revenue ($19.35B) is significantly higher than 2024 Annual ($16.75B), implying potential data volatility or massive recent inorganic growth.
- Consistent earnings beats of exactly +0.0% to +0.1% over 4 quarters suggests aggressive guidance...
- Intense competitive environment
- Consistent earnings beats of exactly +0.0% to +0.1% over 4 quarters suggests aggressive guidance management or potential earnings smoothing to meet targets precisely.